Inogen Gains From Commercial Launch of Wireless Connect

Inogen, Inc.INGN recently announced the commercial launch of Inogen Connect, a new wireless connectivity platform for the Inogen One G4 device, through its direct-to-consumer channel. This is likely to fortify Inogen's foothold in the global respiratory care devices market.

In fact, the company plans to launch Inogen Connect in the domestic business-to-business channel for the Inogen One G4 in the first quarter of 2019.

Following the announcement, shares of the company rose 2% to $128.52 at close.

About Inogen Connect

Inogen Connect is a mobile application for use by oxygen therapy users which has a back-end database portal. Notably, the app is compatible with Apple and Android platforms and includes patient features such as oxygen purity status, battery run time, product support functions, notification alerts, and remote software updates.

For investors' notice, the Inogen One G4 is a single-solution portable oxygen concentrator, capable of providing oxygen. Notably, the company received French reimbursement coverage of the Inogen One G4 in the recent past.

A Peek In to Inogen's Product Portfolio

An expanding product portfolio has been a key catalyst for Inogen.

Apart from One G4, Inogen One G3 portable oxygen concentrator brings mobility and independence to oxygen therapy users. This platform is the lightest continuous flow oxygen concentrator in the market and consumes much less power than its competitive devices. Moreover, OxyGo FIT is a small and light portable oxygen concentrator offered by the company.

Another important platform is Inogen At Home which is aptly formulated for patients who need oxygen therapy during sleep. This patient group is estimated to represent more than 30% of the total oxygen patient base in the United States.

Market Prospects

MarketWatch predicts that the respiratory care devices market will reach a worth of $24 billion by 2022 at a CAGR of 9.7%.

Increase in pollution levels and urbanization and increasing interests in the human services industry propel growth in the market.

Another key player in the space is ResMed Inc. RMD whose CPAP Masks for sleep apnea and breathing assistance deserve a mention here.

Price Performance

We believe positive developments such as these are likely to boost Inogen's shares which have declined 1.5% against the industry 's 5.9% gain over the past year. The current level however compares favorably with the S&P 500 index's 6.4% decline.

Zacks Rank & Key Picks

Inogen currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Integer Holdings Corporation ITGR and OPKO Health, Inc. OPK .

Integer Holdings projects earnings growth rate of 31.2% for the fourth quarter. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

OPKO Health's long-term earnings growth rate is projected at 12%. The stock presently carries a Zacks Rank of 2.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OPKO Health, Inc. (OPK): Free Stock Analysis Report

Integer Holdings Corporation (ITGR): Free Stock Analysis Report

Inogen, Inc (INGN): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More